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1. Introduction 
Natural products are produced by a wide range of different organisms. Microorganisms, 
plants, marine species, and animals employ such compounds for several purposes such as 
building blocks, coenzymes and cofactors, host-defense against microbial infection and 
predators, protection of ecological niches, communication between and within species, 
pigments, cellular signaling, gene expression, and homeostasis maintenance. Currently, 
many key therapeutic classes of drugs in use are derived from natural products, such as the 
antimalarial drug artemisinin, several anticancer agents, the lipid-lowering statins and 
immunosuppressors used to prevent the rejection of tissue grafts (Harvey, 2010). 
Since ancient times, natural products represent the main source of compounds employed in 
drug discovery and development. Still now, nature provides the mankind with a diversity of 
small bioactive compounds, opening promising avenues for the treatment of a great variety of 
diseases. Indeed, through millions of years, natural products have evolved to encompass a 
broad spectrum of chemical and functional diversity that enables them to target of a nearly 
limitless number of biological macromolecules in a highly selective manner. In contrast, 
synthetic molecules generated by combinatorial chemistry show lower chemical diversity and 
selective action than their natural counterparts. Because of these characteristics, natural 
products, mostly plant secondary metabolites, have seen great success as therapeutic agents. In 
fact, about 50% of the drugs introduced in the market during the last 20 years were derived 
directly or indirectly from bioactive compounds. Interestingly, of the approximately 1,200 new 
medicines approved by the FDA in the 25-year period up to 2006, only around one-third of the 
small molecules were completely synthetic in origin, with the remaining being natural 
products, direct derivatives of natural products or synthetic compounds inspired by a natural 
product lead (Vuorelaa et al., 2004; Newman & Cragg, 2009; Harvey, 2010). 
Besides the known diversity of bioactive compounds, it is certain that a great number of 
novel nature-based molecular structural models, with novel biological activities, remain to 
be discovered. It is currently estimated that approximately 420,000 plant species exist in 
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nature; the majority of which still unknown (Vuorelaa et al., 2004). In addition, less than 1% 
of microbes known by humans can be cultivable in laboratory conditions. In fact, the 
therapeutic potential of metabolism-derived microbial products is largely not explored, 
besides the astonishing number of different microorganisms that inhabit the Earth. 
Interestingly, despite our reduced knowledge of the microbial diversity, more than 20,000 
secondary metabolites derived from microorganisms have already been described, while 
only a small percentage of these have been carried forward as natural product drugs 
(Knight et al., 2003). Marine organisms also represent a significant source of bioactive 
molecules, much of which in phase II, phase III and at the commercialization stage of new 
drug development (Galeano et al., 2011). 
According to the World Health Organization (WHO), cancer is the leading cause of death 
worldwide and responsible for around 7 million deaths per year, a number estimated to 
reach 11 million until 2030. However, chemotherapy, the major therapeutic approach for 
cancer treatment, has to deal with important constrains such as lack of aqueous solubility 
and selectivity of antineoplastic drugs and the innate or acquired emergence of multidrug 
resistance by cancer cells. Consequently, there is an overwhelming demand for the 
discovery of novel chemopreventive compounds and to the development of new, more 
potent and effective, anticancer drugs. In this scenario, natural products represent the most 
valuable source of bioactive compounds able to inhibit cancer and serve as leads and 
scaffolds for the development of more efficacious drugs. Indeed, historically, natural 
products have been the most significant source of drugs and drug leads. Currently, around 
74% of the available anticancer compounds are natural products or natural product-derived 
(Tan et al., 2006). With this perspective, in this chapter, we outline the historical importance 
and future perspectives of terrestrial and marine-sourced anticancer agents in oncology, and 
discuss the impact of novel biodiversity sources, such as venoms and toxins from several 
animal species, in anticancer drug development. In addition, some general aspects of 
chemical modifications done in natural products core with the aim to improve their activity 
and/or effectiveness are described. 
2. Plants as a valuable source of anticancer drugs 
Natural products with interesting biological activities and complex chemical structures with 
diverse functional groups result from the phenomenon of biodiversity, which means the 
richness in variety of organisms in the ecosphere (McChesney et al., 2007). These complex 
molecules evolve from a natural source of combinatorial chemistry, directed to select 
specific products with biological advantage. As a consequence of this natural selection, 
molecules able to interact specifically with biological targets arise, thus providing increased 
survival to the organisms that generated them. From a historical point of view, natural 
products have long been used as the mainstay of anticancer pharmacology.  
From Podophyllum peltatum, which provided the podophyllotoxins in the early 1950s, to the 
Pacific yew Taxus brevifolia, from which emerged the most significant anticancer drug 
paclitaxel (Taxol), plants have been a seemingly unimaginable source of effective new drugs. 
Indeed, since the development of the vinca alkaloids, vinblastine and vincristine, and the 
isolation of podophyllotoxins, from which derived the semisynthetic derivatives, etoposide 
and teniposide, plant-derived agents have consolidated their place in the chemotherapy 
armamentarium of anticancer drugs, remaining largely prescribed today and having decades 
of success in the clinical set (Cragg & Newman, 2005; Newman & Cragg, 2007; Bailly, 2009).  
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Drug discovery from medicinal plants is an interdisciplinary and multi-stage process 
characterized by the collection and identification of plant species with known biological 
activities or randomly collected for screening purposes, extract preparation and biological 
screening for pharmacological properties in relevant experimental models, isolation and 
characterization of active compounds, and screening assays directed toward molecular 
targets (Balunas & Kinghorn, 2005). Several strategies have been used to identify new 
compounds for drug discovery, of which natural products, and particularly medicinal 
plants, are still considered an important source of new drugs. Moreover, compounds with 
new biological activities can afford important drug leads in the development of new 
generations of drugs with specific and selective activities against novel molecular targets 
(Balunas & Kinghorn, 2005; Bailly, 2009). During the glory decades, several classes of plant-
derived cytotoxic drugs have entered into clinical trials and some are in clinical use, such as 
camptothecin, isolated from Camptotheca acuminate, the precursor of the topotecan and 
irinotecan, homoharingtonine, isolated from the Chinese tree Cephalotaxus harringtonia, 
flavopiridol, a synthetic flavonoid structurally based in the natural product rohitukine, 
isolated from Dysoxylum binectariferum, combretastatin from the South African “bush 
willow” Combretum caffrum, vinorelbine, the major semi-synthetic tubulin-binding vinca 
alkaloid and the taxanes (Cragg & Newman, 2005; Bailly, 2009). 
The naphthoquinones, mainly lapachol and β-lapachone, are another class of anticancer 
agents that has been received most attention. While lapachol failed in clinical trials due to 
their toxicity, β-lapachone provides significant activity against tumor cell lines from 
different histological origins, including leukemia, breast, prostate and several multidrug 
resistant (MDR) cell lines. In addition to these effects, its ability to inhibit the enzyme Cdc25, 
a dual-specificity phosphatase that promotes cell cycle progression and has been postulated 
to be an oncogene, renewed interest in this family of compounds (Ravelo et al., 2004; 
Karlsson-Rosenthal & Millar, 2006).  
Sesquiterpene lactones encompass a class of terpenoids derived mainly from Asteraceae, but 
also found in Umbelliferae and Magnoliaciae, which have the ability to selectively target 
tumor and cancer stem cells. Artemisinin from Artemisia annua L, thapsigargin from Thapsia 
(Apiaceae) and parthenolide from Tanacetum parthenum and their synthetic derivatives are 
the most promising drugs of this family for cancer treatment (Ghantous et al., 2010). Studies 
indicate that their selectivity against tumor cells is achieved by different mechanisms, 
including modulation of specific signaling pathways, induction of oxidative stress, and 
epigenetic, antiangiogenic and antimetastatic activities. For instance, thapsigargin has been 
shown to inhibit the sarco/endoplasmic reticulum (ER) calcium ATPase (SERCA) pump, 
thus increasing intracellular Ca2+ levels, which ultimately lead to ER stress and cell death 
(Christensen et al., 2009; Winther et al., 2010). Artemisinin has shown promising antitumor 
properties in vitro and in vivo, entering phase I–II clinical trials against metastatic breast and 
colorectal cancers. As tumor cells express higher levels of transferrin receptors on cell 
surface and have higher concentrations of intracellular iron than normal or slow-
proliferating cells, cleavage of artemisinin endoperoxide bridge upon binding to Fe(II) and 
subsequent free radical generation in tumor cells have been associated to its toxicity. As 
simultaneous inactivation of p53 and hyperactivation of nuclear factor κB (NFκB) is a 
common event in human cancers, drugs able to target both pathways have been considered 
interesting candidates for anticancer therapy. Both sesquiterpene lactones, parthenolide and 
artemisinin, are able to inhibit NFκB, rendering cancer cells sensitive to chemotherapy 
(Ghantous et al., 2010). In particular, parthenolide has been shown to inhibit NFκB and to 
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activate p53 by promoting the ubiquitination and degradation of its negative regulator 
MDM2 (Gopal et al., 2009). Furthermore, the elevated NFκB signaling in leukemia stem cells 
compared to normal hematopoietic stem cells has been ascribed to parthenolide selectivity 
against acute myeloid leukemia (Ghantous et al., 2010). A more recent epigenetic role for 
parthenolide in cancer has been shown, by specifically inhibiting DNA methyltransferase 1 
(DNMT1) and histone deacetylase 1 (HDAC1) activities, leading to DNA hypomethylation 
in vitro and in vivo (Liu et al., 2009; Ghantous et al., 2010). 
Also, the ability of plant secondary metabolites, such as vitamins, isothiocyanates, quercetin, 
catechins, resveratrol, epigallocatechin-3-gallate (EGCG), genistein and curcumin, to prevent 
and/or inhibit tumor growth, either alone or in combination with other anticancer drugs 
and/or other phytochemicals has been documented (de Souza et al., 2005; Justo & Ferreira, 
2005; de Souza et al., 2006; Hemalswarya & Doble, 2006; de Souza Queiroz et al., 2007; 
Newman & Cragg, 2007;  de Fátima et al., 2008a; Bailly, 2009; Camargo et al., 2011). In this 
respect, all-trans-retinoic acid (vitamin A) is now widely used for the treatment of myeloid 
leukemia (Sanz & Lo-Coco, 2011) and vitamin D is in clinical trial for this disease (Trump et al., 
2006). Recently, we provided evidence that photoderivatives of riboflavin, a constituent of the 
vitamin B complex (vitamin B2), possess strong activity in hematological malignancy as well 
(de Souza et al., 2006). The molecular mechanism involved the activation of caspase 8 induced 
by overexpression of Fas and FasL and mitochondrial amplification mechanisms associated 
with the stimulation of ceramide production by sphingomyelinase and ceramide synthase. In 
addition, activation of this cascade led to an inhibition of mitogen activated protein kinases c-
Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK) kinase (MEK) and 
ERK and survival mediators [Protein kinase B (PKB/Akt) and inhibitor of apoptosis protein 1 
(IAP1)], upregulation of pro-apoptotic Bax and downregulation of cell cycle progression 
regulators (de Souza et al., 2006). The potential of such vitamin-derived products in solid 
tumors was also demonstrated in androgen-independent human prostate cancer (PC3) cells 
(de Souza Queiroz et al., 2007). As reported earlier, riboflavin photoproducts are cytotoxic to 
these cells in a Fas–FasL-dependent manner. Furthermore, irradiated riboflavin inhibited 
matrix-degrading proteases, caused downregulation of vascular endothelial growth factor 
(VEGF) and upregulation of tissue inhibitor of metalloproteinase 1 (TIMP1), suggesting 
antimetastatic potential (de Souza Queiroz et al., 2007). 
The anticancer properties of curcumin, a natural phytochemical obtained from dried root and 
rhizome of the spice turmeric (Curcuma longa), has long been studied, with few analogues 
showing promising results as future candidates for clinical development (de Fátima et al., 
2008a; Ravindran et al., 2009; Agrawal & Mishra, 2010). Decades of research have 
demonstrated that tumor cell death induced by curcumin occurred by a number of 
mechanisms, mostly by interfering with multiple cell signaling pathways, including the 
intrinsic and extrinsic apoptosis pathways, and the NFκB and phosphatidylinositol 3-kinase 
(PI3K)/Akt signaling cascades. Furthermore, curcumin can be used for cancer prevention and 
it also sensitizes cancer cells to radiation and chemotherapeutic drugs (Kunnumakkara et al., 
2008; Ravindran et al., 2009). 
The flavonoid quercetin, which is abundantly present in fruits, vegetables, wine and tea, has 
revealed several properties such as antioxidant, antiproliferative and anticancer (Boots et al., 
2008; Murakami et al., 2008). Cachexia is a poorly understood syndrome present in already 
compromised cancer patients, decreasing the quality of life and increasing mortality. Several 
studies have been performed in an attempt to find an effective way to treat cachexia, but 
none of the tested therapies has fulfilled expectations. Recently, Camargo and colleagues 
www.intechopen.com
 
The Medicinal Value of Biodiversity: New Hits to Fight Cancer 
 
125 
(2011), have demonstrated that intraperitoneal injections of quercetin reduced cachexia in 
rats bearing Walker 256 carcinosarcoma. Moreover, this effect was accompanied by tumor 
growth inhibition and increased survival. Evaluation of some of the mechanisms involved in 
quercetin activity showed decreased MMP-2 and VEGF levels in treated animals, suggesting 
angio-prevention and mitigation of invasion, effects that strongly support the anticancer 
property of this flavonoid (Camargo et al., 2011). 
Even though plants have been an important source of drugs with great chemical diversity, a 
significant reduction in the number of plant-derived drug candidates occurred since 2000 
(Bailly, 2009). Besides the lack of expected efficacy and toxicity, as well as, reduced aqueous 
solubility and problems with the determination of biological activities of complex extracts, 
which impair the development process of new drug candidates, issues related to difficulties 
with sourcing authenticated plant material and the quantity of drug needed for their 
development are major challenges to be overcome. In addition, the development of effective 
drugs from naturally occurring agents is time-consuming and requires considerable 
resources. These limitations, together with the advent of molecular target-based drug 
discovery programs in the 1990s, significantly impacted the development of the segment of 
natural product-based pharmacology, leading to a decline in the search for new hits 
(Schmidt et al., 2007; Bailly, 2009). Interestingly, the percentage of patents involving natural 
product derivatives remained almost unchanged during this period (Schmidt et al., 2007). 
Furthermore, despite the introduction of synthetic approaches in the universe of drug 
discovery, studies demonstrate that natural products and their derivatives continue to play 
a pivotal role in saving and prolonging the life of millions of patients (Mann, 2002; Newman 
et al., 2003; Cragg & Newman, 2005; McChesney et al., 2007; Newman & Cragg, 2007; Bailly, 
2009). Such incredible better performance of natural products compared to randomly 
synthesized molecules is the consequence of the common evolutionary roots of plant natural 
products, enzymes, receptors and proteins, which arise to interact with one another 
(Schmidt et al., 2007). Thus, the search for drugs from novel biodiversity sources combined 
with the identification of new targets are still considered as one of the most important 
strategies to find innovative drug candidates (McChesney et al., 2007; Schmidt et al., 2007; 
Bailly, 2009), leading to the optimism that novel drugs derived from plants are forthcoming. 
3. The microbial world of anticancer drugs 
In the world of life organisms the primary metabolism represents the anabolic and catabolic 
processes that are essential for organism growth and reproduction. In this way, the primary 
metabolism pathways and the primary metabolites are highly conserved across species, 
genera, and kingdoms. In contrast, the secondary metabolism works for organism adaptation 
and secondary metabolites are produced by individual species or genera for specific 
physiological, social or predatory reasons. These compounds therefore are specie/genera 
specifics and, given the impressing diversity of life organisms on Earth, constitute a valuable 
source of complex and intricate structures with a wide range of biological activities. 
Microbial-derived secondary metabolites are low molecular mass products (<3,000 Daltons) 
characterized by unusual and complex structures. Indeed, competition for survival and 
environmental pressures drive the evolution of defense, attack and signaling diversity, 
which, in turn, determine chemical and biological diversity and potential new drugs. They 
are represented by peptides, polyketides, carbohydrates, lipids, terpenoids, steroids and 
alkaloids, most of which used directly or indirectly as scaffolds for antibiotic, antitumor and 
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cholesterol-lowering drug synthesis. The importance of such compounds in the treatment of 
a wide range of diseases is demonstrated by the fact that 40% of new drugs discovered since 
1980 were derived from natural microbial sources (Koehn & Carter, 2005). 
Environmental microbes – mainly actinomycetes, bacilli and filamentous fungi – have an 
enormous capacity to produce secondary metabolites, which have been exploited for drug 
discovery. By 2002, microbes were the source for 22,500 bioactive compounds. Of these, 17% 
were obtained from unicellular bacteria (mainly Pseudomonas and Bacillus), 45% from 
filamentous bacteria (Actinomycetes) and 38% from fungi (Demain, 2009; Singh & 
Macdonald, 2010). For over 40 years, natural small organic molecules derived from microbes 
and plants have played a very important role as established anticancer chemotherapeutics. 
In particular, microbes have been recognized to contribute significantly to this field. 
Currently, antibiotics with antitumoral activity have been used in the treatment of cancer 
patients as the case of anthracyclines (such as doxorubicin), bleomycin, dactinomycin 
(actinomycin), and mitomycin C (Kinghorn et al., 2009). 
Pericosines A-E are a family of cytotoxic metabolites isolated from Periconia byssoides OUPS-
N133, a fungus that was collected from the sea hare Aplysia kurodai. Among the members of 
this family of carbasugars, pericosine A is the most important, because it was reported to 
possess significant inhibitory activity against protein kinase EGFR (epidermal growth factor 
receptor) and human topoisomerase II, in addition to its antitumor activity against P388 
lymphocytic leukemia cell line in vitro and in vivo (Numata et al., 1997; Yamada et al., 2007). 
Various reports in literature have shown the efforts of researchers to characterize the structure 
of pericosine molecules and develop new routes for their synthesis (Usami et al., 2009). 
Since 1941, when penicillin was introduced in the market, secondary metabolites of bacteria 
have been studied as promising drug candidates for the treatment of diverse pathologies, 
including cancer. Many bacterial products such as proteins, enzymes, immunotoxins, 
secondary metabolites or even naked DNA can be used or adapted in a proper manner to 
specifically target cancer cells, causing tumor regression through growth inhibition, cell 
cycle arrest or apoptosis induction. Interestingly, many bacterial compounds also inhibit 
cancer metastasis.  
Some bacterial enzymes are potential candidate therapeutic agents for cancer treatment. The 
enzyme arginine deiminase (ADI), found in Mycoplasma arginine and P. aeruginosa among 
others, is an example of bacterial product that combat cancer cells through its ability to 
cause arginine depletion and consequent nutritional stress in cancer cells. Curiously, while 
arginine is a nonessential amino acid in humans, some cancers, such as hepatocellular 
carcinoma, melanoma and renal cell carcinomas, do not synthesize arginine, making ADI a 
promising enzyme for the selective elimination of such cancer cells through arginine 
deprivation. Furthermore, the crystal structure of ADI demonstrated that this enzyme 
harbor a putative CARD-like domain (caspase activation domain) with no significant amino 
acid sequence homology. In this way, it seems that ADI could be a selective inductor of 
cancer nutritional stress through its enzyme activity, while in the absence of catalytic 
activity the enzyme could act as a selective inductor of caspase activity and programmed 
cell death in cancer cells (Barile & Leventhal, 1968; Das et al., 2004). Another bacterial 
product that exploit cancer metabolism to induce cell death is L-methioninase, a ubiquitous 
enzyme expressed in all organisms including bacteria, fungi, protozoa, and plants, except in 
mammals. L-Methioninase is a pyridoxal 5′-phosphate dependent enzyme that catalyzes the 
direct γ-conversion of L-methionine to methanethiol, α-ketobutyrate, and ammonia. L-
Methionine is an essential amino acid with several critical functions, including biosynthesis 
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of protein, glutathione, and polyamines, in addition to the methylation of DNA, thus 
regulating gene expression. As in the case of arginine, cancer cells are not able to synthesize 
methionine and need an external supply of this amino acid to keep alive. Thus inhibiting the 
use of methionine by cancer cells through L-methioninase has been pointed as a relevant 
strategy to improve conventional anticancer therapies. However, studies have shown that 
the therapeutic response of the bacterial enzyme is usually associated with high 
immunogenicity, low substrate specificity, and hazardous effects to the kidney and liver. In 
contrast, L-methioninase from eukaryotes may be characterized by their lower 
immunogenicity reinforcing the need for extensive biochemical and pharmacokinetic 
characterization of this enzyme from organisms like fungi, which are able to produce it 
efficiently (El-Sayed, 2010). 
Bacterial products can also combat cancer through inhibition of the HDAC enzyme. 
Romidepsin (FK228), a naturally occurring depsipeptide isolated from Chromobacterium 
violaceum, is a potent HDAC inhibitor with anticancer activity against leukemia, colon cancer 
and neuroblastoma cell lines, human tumor xenografts and murine tumors, and is therefore 
expected to be a novel and promising anticancer drug, currently under clinical evaluation in 
the USA (Ueda et al., 1994; Schrump et al., 2008; Piekarz et al., 2009; Mizutani et al., 2010; 
Panicker et al., 2010). The mechanism of FK228 induction of cancer demise is incompletely 
known but it seems associated with the ability of this compound to induce hydrogen 
peroxide synthesis, activation of caspases and programmed cell death (Mizutani et al., 2010). 
Inhibitors of HDAC are also found in extracts of Pseudomonas. Spiruchostatin A (also known 
as YM753) and B closely resemble FK228, exhibiting greater potency as HDAC inhibitors than 
several other compounds including FK228, making them promising anticancer agents (Crabb 
et al., 2008; Shindoh et al., 2008). In addition to FK228, another major product of C. violaceum 
metabolism, named violacein, has been extensively studied for its several biological activities 
(Durán et al., 2007). Of note, this purple-colored pigment has gained attention for its 
antitumor properties, which has been demonstrated in vitro against a number of cancer cell 
lines from several histological origins, as well as in vivo (Melo et al., 2003; Ferreira et al., 2004; 
Kodach et al., 2006; Durán et al., 2007; Bromberg et al., 2010). Moreover, studies have shown 
the ability of violacein to induce apoptosis by mechanisms that include modulation of a 
number of signaling pathways and the generation of oxidative stress (Melo et al., 2003; 
Ferreira et al., 2004; Kodach et al., 2006; Durán et al., 2007; Bromberg et al., 2010). Importantly, 
treatment of Ehrlich ascites tumor (EAT)-bearing mice with micromolar doses of violacein 
inhibited the tumor volume, the number of viable tumor cells and increased survival, 
differing from other works with natural products in the literature which spend high doses of 
the compounds. In addition to present a lower toxicity to normal cells in vitro, hematology, 
biochemistry and histopathological analyses of liver and kidney of mice receiving daily 
intraperitoneal doses of violacein up to 1 mg/kg indicated that treatment with violacein is 
well tolerated and does not cause hematotoxicity nor renal or hepatotoxicity (Durán et al., 
2007; Bromberg et al., 2005; Bromberg et al., 2010). At this point, it is important to mention 
that the Amazonian strain of C. violaceum (from Rio Negro, Brazil) produces violacein at a 
higher rate compared to other strains, including the ATCC 553 strain, as well as other 
bacteria, such as Janthinobacterium lividum and Alteromonas luteoviolacea. Also, using the 
Brazilian strain, the biotechnological process of violacein production was optimized by our 
group, resulting in higher yields of the compound (Durán et al., 2007).  
Immunotoxins constitute another source of bacterial compounds with potential use in the 
antitumoral therapies. Exotoxin A-immunotoxins, such as that produced by P. aeruginosa, 
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kill cancer cells by binding specifically to overexpressed cell surface receptors, which carries 
them into the cell, where they catalyze the ADP-ribosylation of the eukaryotic elongation 
factor 2 (eEF-2) in host cells, ultimately affecting protein synthesis and inducing 
programmed cell death. Clinical trials with different exotoxin A-immunotoxins have 
demonstrated that such bacterial products present better results in eliminating cells derived 
from hematological malignancies over those originated from solid tumors (Wolf & Elsasser-
Beile, 2009; Bernardes et al., 2010). P. aeruginosa has also been demonstrated to produce 
another immunoglobulin-like product named azurin, a water soluble enzyme involved in 
the electron transport chain. Azurin has its secretion enhanced from P. aeruginosa in 
response to the presence of human cancer cells. Furthermore, azurin is known to enter 
preferentially into cancer cells and has multiple antitumor activities (Mahfouz et al., 2007). 
Azurin binds and stabilizes the tumor suppressor protein p53 besides its ability to bind and 
inhibit the activity of several Ephrin (Eph) receptor tyrosine kinases, a family of extracellular 
receptor proteins known to be upregulated in many tumors. Azurin-induced stabilization of 
p53 results in the increased expression of proapoptotic proteins, thus contributing for the 
triggering of programmed cell death in cancer cells (Xu et al., 2010). Binding and inhibition 
of Eph receptors by azurin avoid the activation of cellular signaling pathways that stimulate 
proliferation, migration, invasion and angiogenesis of many types of human tumors 
(Chaudhari et al., 2007). Interestingly, P. aeruginosa not only secretes azurin, but 
simultaneously releases in the growth medium an extrachromosomal DNA element rich in 
stretches of unmethylated CpG dinucleotides. This molecule demonstrates antitumor 
activity through TLR9 activation and cytokine/chemokine production and allows cancer cell 
death. In addition to P. aeruginosa other bacteria, such as Mycobacterium bovis, also secrete 
unmethylated CpG dinucleotides with antitumor activities (Mahfouz et al., 2007). Recently, 
preclinical studies were done with the azurin-p28 (NSC 745104), an amphipathic, 28 amino 
acid fragment (aa 50-77) of the azurin. The results demonstrated that p28 does not exhibit 
preclinical immunogenicity or toxicity, has a similar metabolic profile among species, and is 
therapeutic in xenograft models (Xu et al., 2010). 
The Ras GTPases (HRAS, NRAS and KRAS) are the founding members of a large 
superfamily of monomeric small (20–25 kDa) GTPases that regulate diverse cellular 
processes, including those associated with cancer progression, such as  proliferation, 
differentiation, cell survival and migration. Mutational activation of Ras is found in about 
33% of human cancers, making these proteins important targets for reaching successful 
cancer treatments (Vigil et al., 2010).  Activation of the Ras oncogene requires the linkage of 
a farnesyl group, allowing the protein anchorage to the cell membrane and the subsequent 
interaction with guanosine exchange factors located in receptor-associated complexes. Some 
Ras family proteins such as KRAS can be alternatively activated through the addition of a 
geranylgeranyl moiety. Farnesyltransferase inhibitors (FTI) are metabolites capable of 
blocking this step, thus impairing Ras activation, even in the presence of a mutant Ras. 
Several FTIs of microbial origin have been discovered in the past few years specially among 
fungi (Vilella et al., 2000; Iwasaki & Omura, 2007). Fungi, like Aspergillus terreus, Monascus 
ruber and Pleurotus ostreatus, produce lovastatin, a member of the drug class of statins, which 
blocks Ras activation through inhibition of farnesylation and induces apoptosis (Laezza et 
al., 2008). Manumycin A, a competitive farnesyltransferase inhibitor, is an antibiotic 
detected in the culture media of a Streptomyces strain that has shown both in vitro cytotoxic 
activity against several cell lines (human pancreatic tumor, breast and colon cancers, thyroid 
carcinoma, leukemias, myeloma and hepatocellular carcinoma) and in vivo against human 
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cancer xenograft models (Bernardes et al., 2010). Gliotoxin is a member of the 
epipolythiodioxopiperazine class of toxins and is both the major and the most potent toxin 
produced by Aspergillus fumigatus. Gliotoxin and KT7595, a gliotoxin derivative, inhibited 
DNA synthesis, cellular proliferation and Ras farnesylation in human colon carcinoma, 
hepatoma and gastric carcinoma (Nagase et al., 1997). 
Many secondary metabolites from bacterial origin have entered clinical trials as antitumor 
drugs. Prodiginines and its derivatives, like prodigiosin and obatoclax, demonstrate 
powerful and selective anticancer activity against several cancer-derived cell lines, while 
little or no activity has been documented against normal cells. Importantly, these bacterial 
metabolites seem to be resistant to multidrug pumps that are often responsible for inducing 
resistance to other anticancer agents (Nguyen et al., 2007). The epothilones were initially 
isolated from the slime mold Sorangium cellulosum as antifungal compounds. Today, this 
class of compounds is recognized by its valuable action as microtubule-stabilizing agents 
that have demonstrated antitumor activity in taxane-resistant models and in cancer cells 
displaying MDR disease. Natural epothilones B and D and many derivatives are under 
investigation in several pre-clinical, and phase I and II clinical trials. At this time, 
ixabepilone (BMS) is the sole drug to reach the market, although sagopilone (Bayer) is 
currently in phase II clinical trials (Beutler, 2011; Nobili et al., 2011). 
Cancer metastasis occurs during tumor progression and causes 90% of human cancer deaths. 
Many bacteria, like Staphylococcus aureus, naturally produce several chemokine/adhesion 
receptor inhibitors, which actions avoid cancer cell migration. Staphylococcal superantigens-
like (SSL) molecules, such as SSL10 and SSL5, showed to bind specific receptors displayed 
by cervical and leukemia cells, inhibiting their ability to spread through other tissues in the 
body (Walenkamp et al., 2009; Walenkamp et al., 2010). 
Finally, cancer treatment can also be done using live, attenuated or engineered bacteria. 
Clostridium, Bifidobacterium, Salmonella, Mycobacterium, Bacillus and Listeria have the ability to 
selectively target cancer cells and act as anticancer agents. They grow in the hypoxic core 
region of solid tumors, where most of the time radiation or chemotherapy is unsuccessful. In 
addition, thanks to their selectivity for the tumor microenvironment, these bacteria are also 
promising vectors for delivering therapeutic genes for anticancer therapies (Bernardes et al., 
2010).  
As discussed here, microbes constitute a great source of anticancer therapeutic compounds. 
Indeed microbes are the most diverse (both structurally and metabolically) and abundant 
group of organisms and account for 60% of the Earth’s biomass. However, genomic studies 
indicate that certain groups of bacteria and fungi have dozens of secondary metabolite 
pathways that are not expressed under standard laboratory growth conditions. In fact, >99% 
of environmental microbes are uncultivable, limiting the discovery of new products (Singh 
& Macdonald, 2010). In this way, understanding community and functional diversity is 
essential for exploiting the potential of microbes as a source of new drugs. Recently, with the 
advent of new technologies and genomic data, the discovery of novel drugs from 
uncultivable microbes has become a reality that brings new opportunities for the 
development of new anticancer drugs. In particular, metagenomics has been highlighted as 
a promising strategy for this goal. Metagenomics allows the extraction of total genetic 
materials from environmental samples followed by its transferring into new host cells, 
mainly Escherichia coli, to generate metagenomic libraries. Using these libraries it is possible 
to study structural and functional diversity by DNA sequencing or to search for new 
products based on sequence mining or functional expression without the need for culturing 
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microbes. In addition, whole genome sequencing have contributed for the discovery of new 
secondary metabolites with therapeutic effects, as the case of the anticancer drugs 
diazepinomicin and Eco-7942, discovered from the genome mining of Micromonospora and 
Streptomyces spp (Singh & Macdonald, 2010). Furthermore, secondary metabolite pathways, 
which are not expressed under standard laboratory growth conditions, can be synthesized 
in the presence of neighboring microbes; a strategy named mixed fermentation. Research to 
date indicates that mixed fermentation can result in increased antibiotic activity in crude 
extracts, increased yield of previously described metabolites as well as previously 
undetected metabolites, analogues of known metabolites resulting from combined pathways 
and, importantly, induction of previously unexpressed pathways for bioactive constituents 
(Pettit, 2009). In conclusion, microorganisms constitute a rich source of potential antitumor 
compounds. Exploring this diverse group of living organisms is a challenge, but a 
promising strategy. In addition, it is certain that the use of genetic approaches and mixed 
fermentation will open new opportunities for the discovery of novel therapeutic compounds 
“hidden” in the genetic information load by such organisms. 
4. Venoms and toxins as potential anticancer drugs 
Anticancer therapy is one of the main areas for the use of proteins and peptides originating 
from animals. Some of these proteins or peptides, when isolated, may bind specifically to 
cancer cell membranes, affecting the migration and proliferation of these cells. Venoms and 
toxins from snakes, scorpions, frogs, spiders, bee, wasps, ants, centipedes and caterpillars 
may hold the promises for treating many types of malignancies, especially with the 
demonstration of complete remission of cancer cells after treatment with molecules derived 
from animal venom. However, studies focusing on the mechanisms by which these venoms 
act are still very recent, and much has yet to be found out about these molecules. 
4.1 Snake venom and toxins 
The presence of anticancer enzymes in snake venom has been reported and phospholipase 
activity, found in cobra venom, was ascribed to be the enzyme with anticancer potential 
(Braganca & Khandeparker, 1966). Phospholipase B in the venom of the Australian elapid 
snake was cytotoxic to cultured rhabdomyosarcoma cells (Bernheimer et al., 1987). 
Phospholipase A2 (PLA2), isolated from Bothrops newweidii venom, has cytotoxic activity in 
B16F10 melanoma cells (Daniele et. al., 1997), and two toxic PLA2 have been purified from 
the Indian cobra (Naja naja naja) venom, which are neurotoxins presenting cytotoxicity 
against EAT cells (Basavarajappa & Gowda, 1992).  
The Arg-Gly-Asp (RGD)-containing disintegrins are non-enzymatic proteins that inhibit 
cell-cell interactions, cell-matrix interactions, and signal transduction. Disintegrins also have 
the ability to inhibit several aspects of tumor cell behavior, both in vitro and in vivo, 
including adhesion, migration, invasion, metastasis and angiogenesis (Swenson et al., 2007). 
A disintegrin named Salmosin was isolated from Korean snake venom and effectively 
suppressed growth of metastatic tumor, as well as solid tumor in mice (Kang et al., 1999). 
Contortrostatin, a dimeric disintegrin isolated from Southern copperhead snake venom, 
prevented invasion of human breast cancer cells through an artificial matrigel basement 
membrane. Phospholipases, disintegrins and other enzymes of snake venom could progress 
as a therapeutic tool in the treatment of various cancers and thrombotic diseases in the near 
future (Gomes et al., 2010). 
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4.2 Scorpion venom and toxins 
The repertoire of scorpion venoms presents a complex mixture of a large variety of 
molecules that play an important role in the defense and capture of prey. They contain 
mucopolysaccarides, phospholipases, hyaluronidases, protease inhibitors, low molecular 
weight molecules such as serotonin and histamine, histamine releasing peptides, inorganic 
salts, mucus, and many basic small proteins known as neurotoxic peptides (Martin-
Eauclaire & Couraud, 1995). The neurotoxic peptides have specific interaction with ion 
channels, making scorpion venom capable of binding specifically to certain types of cells, 
such as cancer cells. Therefore, this type of venom holds molecules that are of interest to the 
pharmaceutical industry in terms of drug design and development. Scorpion toxins are 
important molecules to fight cancer, since they have shown both in vitro and in vivo effects in 
cancer cells, as well as in phase I and phase II clinical trials. The most studied peptides are 
the long chain toxins composed of 60–70 amino acid residues cross-linked by four disulfide 
bridges. These peptides activate mainly Na+ channels. They are divided in two major 
classes: a-toxins and b-toxins (Possani et al., 2001). Short chain toxins with 30–40 amino acid 
residues cross-linked by three disulfide bridges form another polypeptide family, acting 
mainly upon K+ or Cl- channels. The venom also contains peptides without disulfide bridges 
that act in other targets besides ion channels (Goudet et al., 2002). 
Chlorotoxin (Cltx) is a peptide from the species Leiurus quinquestriatus that inhibits chloride 
influx in the membrane of glioma cells. This peptide binds only to glioma cells, displaying 
little or no activity at all in normal cells. The toxin appears to bind MMP-2 (Deshane et al., 
2003; Veiseh et al., 2007), an extracellular matrix enzyme that exhibits gelatinase activity. 
MMP-2, a proteinase involved in tumor invasion, is specifically upregulated in gliomas and 
related cancers, but is not expressed in normal brain cells. Cltx binds effectively to MMP-2 
endogenously expressed by glioma cells (Deshane et al., 2003; Veiseh et al., 2007) and its 
exposure to Cltx results in loss of gelatinase activity, disruption in chloride channel currents, 
reduction in both MMP-2 and chloride channel expressions, and internalization of chloride 
channels (Veiseh et al., 2007). Thus, these data indicate that venoms from scorpions 
represent important candidates for the development of new clinical treatments against 
tumors. However, further studies are necessary to isolate and characterize their active 
molecules (Heinen et al., 2011).  
4.3 Spider venom and toxins 
Spider venoms contain a complex mixture of proteins, polypeptides, neurotoxins, nucleic 
acids, free amino acids, inorganic salts and monoamines that cause diverse effects in 
vertebrates and invertebrates (Ori & Ikeda, 1998). Regarding the pharmacology and 
biochemistry of spider venoms, they present a variety of ion channel toxins, novel non-
neurotoxins, enzymes and low molecular weight compounds (Rash & Hodgson, 2002). The 
enzyme phospholipase D has been isolated and purified from the venom of brown spider 
that displays high hemolytic activity (Silva et al., 2004), which could present anticancer 
action. Also, hyaluronidases found in the venom of some spiders could be used to increase 
tissue permeability, thus facilitating the penetration of some drugs, or even being employed 
directly as antitumor agents (Girisk & Kemparaju, 2007). Other toxins that have been 
isolated are the oxyopinins from the wolf spider Oxyopes kitabensis, which form pores in 
lipid membranes (Corzo et al., 2002) and could also be considered as candidates for 
anticancer therapy (Shaposhnikova et al., 1997).  
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Psalmotoxin 1 isolated from a West Indies tarantula, is a 40-amino acid peptide that inhibits 
cation currents mediated by acid-sensing ion channels (ASIC) (Escoubas et al., 2000). Bubien 
and colleagues (2004), using this molecule, inhibited Na+ currents in high-grade human 
astrocytoma cells (glioblastoma multiforme, or GBM) (Bubien et al., 2004). The antitumor 
activity of a potent antimicrobial peptide isolated from hemocytes of the spider 
Acanthoscurria gomesiana, named gomesin, was tested in vitro and in vivo (Rodrigues et al., 
2008). Gomesin showed cytotoxic and antitumor activities in cell lines, such as melanoma, 
breast cancer and colon carcinoma.  
4.4 Toad and frog venoms and toxins 
The experiments with the skin extract (TSE) of common Indian toad (Bufo melanostictus, 
Scheneider) exhibited significant antineoplastic activity against EAT cells and human leukemia 
cell lines U937 and K562 (Giri & Gomes, 2004). Leukemia growth inhibition due to TSE was 
mediated by cell cycle arrest in G1 phase. A large number of early and late apoptotic cells were 
found in TSE-treated leukemia cells as compared to the untreated cells (Giri et al., 2006). 
Bufadienolides are molecules present in the skin of toad of the genus Bufo. The cytotoxic 
activity of toad bufadienolides was described in primary liver carcinoma PLC/PRF/5 cells 
(Kamano et al., 1998). Cinobufagin was isolated from Bufo siccus and showed in vitro inhibitory 
effect in five types of human cancer cells (Chen et al., 1998).  The cytotoxic activity of bufalin 
and cinobufagin in prostate cancer cells was associated with constant increase in Ca2+, leading 
to apoptosis (Yeh et al., 2003). Brevinin-2R, a non-hemolytic defensin has been isolated from 
the skin of the frog Rana ridibunda. It showed pronounced cytotoxicity towards malignant cells, 
including Jurkat (T-cell leukemia), B-cell lymphoma, colon carcinoma, fibrosarcoma, breast 
adenocarcinoma and lung carcinoma (Ghavami et al., 2008).  
4.5 Bee and wasp venoms and toxins 
The melittin and PLA2 are two substances that have been isolated and characterized from 
bee venoms. Several studies have been published showing their antitumoral effects (Ownby 
et al., 1997). The melittin enzyme exhibits antimicrobial activities and proinflammatory 
effects (Sumikura et al., 2003), besides inducing perturbations in the cell membrane and 
damage to enzyme systems (Wade et al., 1990). Several cancer cells, including leukemia, 
renal, lung, liver, prostate, bladder, and mammary cancer cells, can be targets of melittin 
(Son et al., 2007). Melittin has also been reported as a PLA2 activator, increasing the calpain 
activity and cell necrosis in the hepatocellular carcinoma (Arora et al., 1996).  
Research involving wasps shows a complex gland responsible for the production and 
injection of venom, which exhibits physiological, pharmacological and biochemical 
activities, playing a role in a variety of survival mechanisms such as defense against 
predators and prey capture, among others (Yu et al., 2007). Mastoparan, a peptide obtained 
from wasp venom has been reported to induce the formation of the mitochondrial 
permeability transition pore (Pfeiffer et al., 1995), and based on its capacity to induce 
mitochondrial permeability and the lack of specificity for tumor cells, Yamada and 
colleagues (2005) encapsulated this molecule with a transferrin-modified liposome with a 
pH sensitive fusogenic peptide (GALA), for selective delivery to mitochondria of K562 cells. 
This liposome targeted cells having high expression of transferrin receptors, which mediate 
its internalization by endocytosis. Results have shown that the encapsulated mastoparan 
was able to release cytochrome c, indicating its potential as an anticancer agent (Yamada et 
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al., 2005). Fujiwara and colleagues (2008) determined the structure of an anticancer molecule 
from Vespa simillima. This molecule is a biologically active quinone, 7,8-seco-p-ferruginone 
(SPF), which exhibited growth inhibitory effect in rat liver cancer cells. The analyses suggest 
that its cytotoxic activity is related to the morphological changes that induce apoptosis of 
cells exposed to this molecule (Fujiwara et al., 2008).  
4.6 Ant, centipede and caterpillar venoms and toxins 
The solenopsin A is a primary alkaloid from the fire ant Solenopsis invicta, having antiangiogenic 
activity. In order to analyze the antiangiogenic activity, studies were conducted to investigate 
the ability of this toxin to inhibit a series of kinases involved in this process (Bai et al., 2003).  
An important study reporting centipede venom antitumor action has shown that a synthetic 
compound, Manβ(1-4)[Fucα(1-3)]Glcβ1-Cer, (glycosphingolipid 7), from Parafontaria laminate 
armigera, exhibits antiproliferative effects in melanoma cells. This compound suppressed the 
activation of the focal adhesion kinase (FAK) and ERK pathways, which are both involved 
in melanoma cell proliferation (Sonoda et al., 2008).  
The cecropins are a group of peptides isolated from the hemolymph Hyalophora cecropia that 
display antimicrobial activity (Andreu et al.,1985), and have been used as potent anticancer 
agents against a variety of tumor cell lines (Suttmann et al., 2008). The mechanism of action 
of cecropins against tumor cells appears to involve the formation of pores in the membrane 
of cells (Chen et al., 1997).  
Lonomia obliqua induces a hemorrhagic syndrome in humans that accidentally get in touch 
with its urticating spines. Many molecules from the venom of L. obliqua have been isolated and 
characterized, including fibrinogenases (Pinto et al., 2006; Veiga et al., 2003), hyaluronidases 
(Gouveia et al., 2005) and an antiapoptotic protein (Souza et al., 2005). The PLA2 hydrolizes 
the sn-2 bond in phospholipids, generating fatty acids and lysophospholipids. The so formed 
lysophospholipids affect the lipid bilayer of cell membranes, leading to cell lysis, while the 
generated arachidonic acid promotes the activation of caspases and release of cytochrome c, 
culminating in apoptosis in some cell types (Zhao et al., 2002).  
It is clear from these data that venoms and toxins from animals can present important 
pharmacological activities in human physiology. The substances found in the venom of 
these animals present great potential as antitumor agents. The understanding of the 
molecular basis of the envenomation processes caused by venoms from snakes, spiders, 
scorpions, frog, toad, caterpillars and bees are important for the diagnosis and treatment of 
the clinical profile, but research in the near future with venoms and toxins will definitely add 
information in the area of cancer biology.  
5. Anticancer drugs from marine life 
The biological diversity of the marine environment is an untapped source of compounds 
with several bioactivities and, therefore, is an extraordinary resource for the discovery of 
new anticancer drugs. The marine environment corresponds to 95% of the biosphere, and all 
except one of the 33 animal phyla are represented in aquatic environments. In addition, 
there are several organisms that are found in marine environment like seaweed, jellyfishes, 
and anemones. The majority of marine species are found near the coast, where there is a 
high number of species, being one of the most productive environments, with an impressive 
biodiversity. The large number of organisms living in this habitat is constantly fighting. One 
of the weapons used in these battles are molecules that are synthesized by marine species. 
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Many of these molecules have important activities for humans, including medicinal 
properties, such as antitumor. Invertebrates and seaweeds are sources of anticancer drugs 
from marine resources (Lin et al., 2010). In this section, we highlight the past and current 
status of several marine anticancer compounds from different marine groups. 
5.1 Anticancer secondary metabolites 
The past decade witnessed a dramatic increase in the number of preclinical anticancer lead 
compounds from diverse marine life entering human clinical trials and several mechanisms 
of action were suggested. An example is agosterol A, which reversed the resistance to 
colchicine in KB-C2 cells (P-glycoprotein (P-gp)-mediated multidrug resistant cells) and also 
the resistance to vincristine in KB-CV60 cells (multidrug resistance-associated protein 
(MRP1)-mediated multidrug resistant cells), because it directly inhibited drug efflux 
through P-gp and/or MRP1 pumps (Aoki et al., 2001).  
Cephalostatin, a bis-steroidal isolated from the tube worm Cephalodiscus gilchristi, induces 
selectively second mitochondria-derived activator of caspase (Smac)/direct IAP binding 
protein with Low pI (DIABLO), but no cytochrome c release from mitochondria. 
Nevertheless, caspase 9 is required for apoptosis induction. Interestingly, caspase 9 is 
activated without the participation of the apoptosome (Rudy et al., 2008). Recently, its 
enantioselective synthesis was described (Fortner et al., 2010).  
Bistramine A is a polyketide derivative isolated from ascidian such as Lissoclinum bistratum, 
but it is also found in a tunicate Trididemnum cyclops (Murphy et al., 2009). This compound 
disrupted the actin cytoskeleton, depolymerized F-actin in vitro and bound directly to 
monomeric G-actin (Rizvi et al., 2010).  
Laulimalide was isolated in 1999 from the marine sponge Cacospongia mycofijiensis. This 
molecule stabilizes microtubules in a similar manner to paclitaxel, but it does not bind to the 
taxoid site on tubulin. It also kills cells resistant to epothilones and paclitaxel (Pryor et al., 
2002; Khrapunovich-Baine et al., 2011). Other pharmacological information of several 
marine intermediate metabolites, with previously determined or undetermined mechanisms 
of action, is summarized in Table 1.  
5.2 Anticancer sulfated polysaccharides 
Marine sulfated polysaccharides are found mainly in seaweeds (green, red and brown 
seaweeds). The well known antitumor polysaccharides from red seaweed are 
homogalactans, and from brown algae are α-L-fucose-containing sulfated homo and 
heteropolysaccharides, called fucan and fucoidan, respectively. There is a greater incidence 
of anticoagulant activity in extracts of the brown algae compared to red and green algae. 
Few studies describe the presence of anticancer sulfated polysaccharides in green algae, 
which are mainly heteropolysaccharides (Jiao et al., 2011). 
The λ-carragennan (sulfated galactan) from the red seaweed Chondrus ocellatus did not 
inhibit sarcoma S180 and H22 hepatocarcinoma cells in culture. However, when these cells 
were implanted subcutaneously in mice, the λ-carragennan inhibits the growth of the 
tumors, supporting a role for the immune system in the antitumor activity of these 
compounds (Zhou et al., 2004). A sulfated galactan, porphyran, extracted from Porphyra 
yezoensis, induces caspase 3 activation and apoptosis in AGS gastric cancer cells without 
affecting the growth of normal cells (Kwon & Nam, 2006). A sulfated heteropolysaccharide 
obtained from the green seaweed Capsosiphon fulvescens inhibits AGS gastric cancer cell  
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Source   
Sponges Compound Mechanism of action 
Halichondria okadai Halichondrin B  Inhibits tubulin polymerization 
Discodermia dissolute Discodermolide Induces a senescent phenotype 
Pseudoceratina 
purpurea 
Psammaplins Activates PPRγ; inhibits DNMT and HDAC  
Hemiasterella minor Hemiasterlin Antitubulin activity 
Agelas mauritianus Agelasphin Immunostimulant compound 
Jaspis digonoxea Bengamide B 
derivative 
Methionine aminopeptidase 
Xestospongia sp. Aaptamine G2/M cell cycle arrest; affects p21 activity 
Reniera sarai Alkylpyridinium 
salts 
Cholinesterase inhibitor 
Mycale adhaerens 13-Deoxytedanoli Binds to the 60S large ribosomal subunit and 
inhibits polypeptide elongation 
Petrosia sp. Dideoxypetrosynol  Caspases 3 and 9 activation; degradation of 
poly(ADP-ribose) polymerase (PARP)  
Cliona varians CvL lectin Caspase-independent cell death; Lysosomal 
cathepsin B-mediated cell death 
Tunicates Compound Mechanism of action 
Ecteinascidia turbinate Ecteinascidin 743 Tubulin inhibition  
Aplidium albicans Dehydrodidemnin 
B 
Ornithine decarboxylase; interruption of 
tumor cell cycle at G1 and G2.  




Vitilevuamide Inhibits tubulin polymerization 
Cystodytes dellechiajei Ascididemin Telomerase inhibitor; activation of caspase 2 
and JNK 
Molluscs Compound Mechanism of action 
Dolabella auricularia Dolastatin 10; 
Synthadotin 
Binds to tubulin 
Elysia rufescens Kahalalide F Induces cell death via oncosis, preferentially 
in tumor cells 
Lamellaria sp. Lamellarin D Inhibitor of DNA topoisomerase I 
Mactromeris polynyma Spisulosine Promotes intracellular ceramide accumulation 
and Protein kinase Cζ (PKCζ) activation 
Ecteinascidia turbinata Trabectedin Production of superoxide near the DNA 
strand, resulting in DNA backbone cleavage 
Aplysia kurodai Aplyronine A Binds to hydrophobic cleft in actin molecule 
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Bacterium Compound Mechanism of action 
Lyngbya majuscula Laxaphycins A & B Increases polyploidy 
Salinispora tropica Salinosporamide A Proteasome inhibitor 
Several species Cryptophycin Antimicrotubule agent 
Symploca sp. Belamide A Antimitotic 




Thiocoraline DNA-polymerase inhibitor 
Other Compound Mechanism of action 
Clavularia viridis (soft 
coral) 
Bromovulone Activation of caspase 12 
Clavularia viridis  Clavulone II Induces the disruption of mitochondrial 
membrane potential and activates caspases 8, 
9 and 3; downregulates cyclin D1 expression 
and promotes cell cycle arrest in G1 phase 
Squalus acanthias 
(shark) 
Squalamine Induces phospholipid bilayer disruption 
Bugula neritina 
(bryozoans) 
Bryostatin Modulator of several protein kinases 
Pentacta quadrangulari 
(sea cucumber) 
Philinopside A Cytotoxic and antiangiogenic 
Several fungus Verrucarin A Protein synthesis inhibitor 
Table 1. Marine anticancer compounds from several sources and their suggested mechanisms 
of action (Amador et al., 2003; Simmons et al., 2005; Paleari et al., 2006; Mayer & Gustafson, 
2008; Sánchez et al., 2008; Queiroz et al., 2009; García et al., 2010; Taniguchi et al., 2010). 
proliferation and induces apoptosis by inhibiting the insulin-like growth factor 1 receptor 
signaling and the PI3K/Akt pathway (Know & Nan, 2007).  Sulfated polysaccharides from 
Caulerpa cupressoides, Caulerpa prolifera, Caulerpa sertularioides and Codium isthmocladum have 
also been demonstrated to inhibit HeLa cell proliferation (Costa et al., 2010). Sulfated 
polysaccharides from L. saccharina, L. digitata, F. serratus, F. distichus and F. vesiculosus 
strongly blocked MDA-MB-231 breast carcinoma cell adhesion to platelets, an effect that 
might have critical implications in tumor metastasis (Cumanshi et al., 2007). In addition, a 
fucan from Spatoglossum schröederi shows anti-adhesive activity by binding directly to 
fibronectin (FN), and blocking FN sites that are recognized by cell surface ligands, possibly 
the integrin family of proteins (Rocha et al., 2005). 
The heterofucan from Undaria pinnatifida induces apoptosis in A549 human lung carcinoma 
cells through downregulation of the antiapoptotic protein Bcl‐2 and activation of caspases. 
This heterofucan also downregulated p38 mitogen-activated potein kinase (p38 MAPK) and 
PI3K/Akt, while the ERK1/2 pathway was activated (Boo et al., 2011). Additionally, literature 
reports that fucans are able to induce cell death by mechanisms independent of caspases. For 
instance, Aisa and colleagues (2005) showed human lymphoma HS-Sultan cell death induced 
by a fucan from Fucus vesiculosus through activation of the ERK signaling pathway (Aisa et al., 
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2005). Hyun and colleagues (2009) also provide evidence that the proapoptotic effect of this 
fucan is mediated by ERK and p38 MAPK activation, and PI3K/Akt inhibition in HCT-15 
colon carcinoma cells (Hyun et al., 2009). Moreover, F. vesiculosus-derived fucan also affected 
the NFκB pathway (Nakamura et al., 2006). Recently, a heterofucan from Sargassum filipendula 
induces apoptosis in HeLa cells mainly by the mitochondrial release of apoptosis-inducing 
factor (AIF) into cytosol. Additionally, in SF-1.5v cells, the expression of Bcl-2 is decreased, in 
contrast to the increased expression of the apoptogenic protein Bax (Costa et al., 2010). 
The marine environment is a major source of anticancer molecules. In recent years, more 
than 2,000 molecules were found. Here we describe a few with known mechanisms of 
action. They represent potential candidates for the treatment of malignant disease, either to 
be used as single agents, or as part of a combination regimen. In addition, they provide a 
very good tool to discover novel targets, which might be important in the understanding 
and treatment of chemoresistant cancer. However, there are marine environments that are 
very poorly studied, as regions below 100 m depth. Besides this, many marine 
microorganisms cannot yet be cultivated. These indicate that there are still several marine 
anticancer agents to be discovered. 
6. Drug design based on natural products 
As highlighted in the above sections, natural products are still major sources of innovative 
therapeutic agents for cancer, as well as for infectious diseases, lipid disorders and 
immunomodulation (Cragg et al., 1997; Newman et al., 2003; Butler, 2004; Lee, 2004; Butler, 
2005; Newman & Cragg, 2007). However, the complexity of many natural products as well as 
the fact that they are present in the nature can limit the scope for making chemical 
modifications to optimize their therapeutic use. Moreover, obtaining a renewable supply of 
active compounds from biological sources may be problematic. Despite these barriers, total 
synthesis of the potent anticancer natural product discodermolide, recently performed in 
multigram scale (Mickel et al., 2004a; Mickel et al., 2004b; Mickel et al., 2004c; Mickel et al., 
2004d; Mickel et al., 2004e), demonstrates that synthetic organic chemistry is a powerful tool 
for increasing efficiency of natural products of limited supply, those with very complex 
structures or those that present no biological desired properties (Nicolaou & Sorensen, 1996; 
Nicolaou & Snyder, 2003). In this chapter section, we describe two examples of chemical 
modifications done in natural products core to improve their activity and/or effectiveness. The 
molecules in focus are podophyllotoxin and goniothalamin, natural products that exhibit 
anticancer properties. The former substance was the lead compound for the development of 
etoposide, teniposide and etopophos, three widely used anticancer drugs, while 
goniothalamin still have work to do on it to get good clinical effects in vivo. Both molecules 
exemplify how important is the biodiversity as a source of chemical weapons to fight cancer. 
6.1 Podophyllotoxin: from natural sources to drugs 
Podophyllin, a resin produced by species of the genus Podophyllun (Berberidaceae), is 
traditionally known to have biological properties such as purgatives, antihelminthic, 
vesicant, antiproliferative, anti-venereal warts, and anti-cough agents (For excellent reviews 
of the historical aspects of the podophyllotoxins see: Imbert, 1998; Canel et al., 2000; 
Gordaliza et al., 2004). The major component of podophyllin, podophyllotoxin (Fig. 1), was 
isolated from this resin in 1881 by Podwissotzki (Podwyssotzki, 1881 and 1882). Among all 
biological properties of podophyllotoxin, its antitumor activity is the most explored.  
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Podophyllotoxin-β -D-glucopyranoside 4'-Demethylpodophyllotoxin-β -D-glucopyranoside
β -Peltatin-β -D-glucopyranoside α-Peltatin-β -D-glucopyranoside
 
Fig. 1. Structure of podophyllotoxin, glycosides and synthetic derivatives. 
Podophyllotoxin is effective in the treatment of Wilms’ tumor, genital tumors, non-Hodgkin 
and other lymphomas, and lung cancer (Utsugi et al., 1996; Subrahmanyam et al., 1998; Liu 
et al., 2007). However, the gastrointestinal toxicity of this compound was unacceptable 
(Greenspam et al., 1950; Leiter et al., 1950). Inspired by the potential antitumor activity of 
podophyllotoxin, the chemists Hartmann F. Stähelin and Albert von Wartburg, working at 
the Sandoz Company in the mid-1950s, synthesized a large number of podophyllotoxin-
derivatives aiming to obtain analogues more active, more water soluble and exhibiting less 
gastrointestinal toxicity (Stähelin & von Wartburg, 1991; Canel et al., 2000). Their first 
thought was that glycoside derivatives may be present in the plant and that such derivatives 
may be less toxic and certainly less hydrophobic than the corresponding aglycones. 
Indeed, by modifying the procedures of extraction of podophyllin, these chemists were 
able to isolate four novel glycosides: podophyllotoxin-β-D-glucopyranoside, 4’-
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β-D-glucopyranoside (Fig. 1) (Stähelin & von Wartburg, 1991) and these glycosides were 
more soluble and less toxic. However, the antitumor activities of glycosides were also 
reduced. Efforts were than directed to chemically modify the glycosides to enhance their 
cytotoxic activities against cancer cells and from this task force, a range of nearly 600 
podophyllotoxin-derivatives were synthesized (Canel et al., 2000).  
Two semisynthetic podophyllotoxin-derivatives etoposide and teniposide (Fig. 1), products 
of condensation of 4’-demethylpodophyllotoxin-β-D-glucopyranoside with acetaldehyde 
and 2-thiophenecarboxaldehyde, respectively, showed to have good clinical effects against 
cancer cells (Stähelin & von Wartburg, 1991 and cited references). Additionally, etoposide 
and teniposide, have potent cytotoxicity in several cancer cell lines, including testicular and 
small cell lung cancer, lung cancer, lymphoma, leukemia and Kaposi’s sarcoma; however, 
they were still less soluble than the corresponding glycoside (Gordaliza et al., 2004). To 
overcome solubility problems, the Bristol-Myers Squibb Co., Princeton, New Jersey, USA, 
developed the etoposide phosphate derivative (etopophos®), which was better suited for 
intravenous administration. In 1996 the US Food and Drug Administration approved this 
prodrug for having similar pharmacological and pharmacokinetic profiles of the parent 
compound, but different solubilities. In fact, the bioavailability in vivo was 1,250-fold 
increased using this prodrug, which is an important improvement of etoposide formulation 
(Schacter et al., 1994; Budman, 1996; Greco & Hainsworth, 1996). 
It is noteworthy to mention that the traditional sources of podophyllotoxin as raw material 
will not attend the increasing demand of this substance to produce their derivatives 
etoposide, teniposide and etopophos®. Currently, approximately 298 clinical trials are under 
way to test these derivatives for new indications and/or new formulations. Each year more 
podophyllotoxin-derivatives are synthesized and evaluated as new chemical entities for 
cancer treatment (Liu et al., 2007). This scenario requires an urgent effort to develop short 
synthetic routes and/or the use of genetic engineering to manipulate the biosynthetic 
pathways of podophyllotoxin in order to increase the synthetic and natural sources of an 
important molecule for human healthy. In summary, podophyllotoxin is a classical example 
of the importance of biodiversity in furnishing new chemical entities and how powerful is 
the organic chemistry to increase the efficiency of natural products to get useful drugs to 
fight cancer. 
6.2 Goniothalamin: a lead compound for drug design? 
Phytochemical studies of the genus Goniothalamus have resulted in the isolation and 
characterization of many compounds with a variety of biological activities (Blázquez et al., 
1999; de Fátima et al., 2006a). The styryl lactones and acetogenins of Annonaceae are a 
group of secondary metabolites mainly isolated from this genus (Bermejo et al., 2005; de 
Fátima et al., 2006a). The natural form of goniothalamin [(R)-goniothalamin; Fig. 2] is the 
styryl lactone most extensively studied and its promising antiproliferative activity have 
prompted scientists to investigate with more details its potential as antitumor agent (Zhou 
et al., 2005; de Fátima et al., 2006a and cited references; Dumitrescu et al., 2010; Wach et al., 
2010; Vendramini-Costa et al., 2010; Kasaplar et al., 2010). This natural compound displayed 
in vitro cytotoxic effect especially by inducing apoptosis in different cancer cell lines (Ali et 
al., 1997; Pihie et al., 1998; Inayat-Hussain et al., 1999; Inayat-Hussain et al., 2003; Chen et al., 
2005; de Fátima et al., 2005; Chan et al., 2006; de Fátima et al., 2008b; Inayat-Hussain et al., 
2010). This effect was shown to be selective for cancer cell lines with no significant 
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cytotoxicity toward non-malignant cells (Pihie et al., 1998; de Fátima et al., 2005 and cited 
references). In in vivo models, (R)-goniothalamin was reported to have tumoricidal and 
tumoristatic activities in Sprague–Dawley rats with 7,12-dimethylbenzanthracene (DMBA)-
induced mammary tumors and in Ehrlich solid tumor in mice (Meenakshii et al., 2000; 
Vendramini-Costa et al., 2010). Although the biological activities exhibited by the natural 
form of goniothalamin (6R absolute configuration) have been widely investigated, no 
studies about the biological activities of (S)-goniothalamin (Fig. 2) were reported up to 2005 
(de Fátima et al., 2006b; Kasaplar et al., 2009). Recently, we have described not only the 
synthesis, but also the antiproliferative activities of both (R)- and (S)-goniothalamin. 
Interestingly, we found that (S)-goniothalamin (IC50 = 6.4 μM) was 1,600-fold more potent 
than (R)-goniothalamin (IC50 = 4.0 nM) in renal 786-0 cancer cells (de Fátima et al., 2006b). 
As reported for (R)-goniothalamin (Pihie et al., 1998; de Fátima et al., 2005 and cited 
references), we demonstrated that (S)-goniothalamin exhibited pronounced selectivity for 
cancer cells, while presenting minor cytotoxicity against non-tumor cells (de Fátima et al., 
unpublished results). The extremely high antiproliferative activity and selectivity presented 
by (S)-goniothalamin for 786-0 cell line (IC50 = 4.0 nM) prompted us to synthesize eigth 
analogues (compounds 1-8; Fig. 2) to identify the pharmacophoric groups responsible for 
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Fig. 2. Structure of natural goniothalamin and its synthetic analogues. 
We found that (S)-goniothalamin was 4,750- and 5,200-fold more potent in inhibiting 
proliferation of kidney cancer cells (786-0) than analogues 1 and 3, respectively (de Fátima et 
al., 2006b). Remarkably, analogue 4 with a cyclohexyl substituent conserved the same 
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cytotoxic activity as (S)-goniothalamin against renal 786-0 cancer cells, being active at the 
nanomolar level (IC50 = 5 nM). No antiproliferative activity was found for analogue 2 under 
our experimental conditions. These results demonstrate that the endo and exo double bonds 
in the pyranone ring are essential for the activity of (S)-goniothalamin against 786-0 cells. It 
is noteworthy that analogues 1, 2, and 3 lacking either one or both double bonds had much 
lower activity than (S)-goniothalamin (de Fátima et al., 2006b). Recently, the importance of 
the E-configuration of the styryl moiety in (R)-goniothalamin for its antiproliferative activity 
was shown (de Fátima et al., 2005) and the α,β-unsaturated lactone group has already been 
implicated in the biological activity of other natural lactones such as cytostatin (Bialy & 
Waldmann, 2003) and fostriecin (Buck et al., 2003). This behavior is most probably due to its 
role as a Michael acceptor for nucleophilic amino acid residues (cysteine, lysine, serine or 





























































Fig. 3. A: Pharmacophoric groups of goniothalamin identified by the cytotoxicity in renal 
cancer cell line (786-0); B: Percentage growth of 786-0 cells after 48 h of treatment with 
different concentrations (0.25, 2.5, 25 and 250 μg/mL) of (S)-goniothalamin and its 
analogues 1 to 8. Positive values in relation to y axis correspond to cytostatic activity, while 
the others refer to the cytotoxic activity of the compound analyzed. 
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Interestingly, (R)-analogue of 1 and 2 were shown to be the main metabolites detected and 
identified in urine and blood samples of (R)-goniothalamin-treated Sprague–Dawley rats, 
thus signaling the double bond reduction in (R)-goniothalamin as a potential detoxification 
route in this species (El-Sharkaway et al., 1996). Moreover, the results obtained from the 
treatment of renal cancer cells with pyranones 5 to 8 demonstrated that electron-donating or 
electron-withdrawing groups in the aromatic ring decreased their potency when compared 
to (S)-goniothalamin. Overall, the findings for renal 786-0 cancer cells suggest that aromatic 
ring or cyclohexyl in (S)-goniothalamin and 4, respectively, likely interacts with a 
hydrophobic domain of a biomolecule present in the cancer cell since these compounds 
were shown to be the most active in inhibiting cell proliferation at nanomolar concentrations 
(de Fátima et al., 2006b). From all these results, we have identified the pharmacophoric 
groups of goniothalamin as presented in Figure 3. 
Goniothalamin represents an interesting example of the different sensitivity of cell lines to 
enantiomers compounds. Indeed, not only a distinct cytotoxicity profile was described for 
(R)- and (S)-goniothalamin but also different mechanisms of action were described (de 
Fátima et al., 2006b; de Fátima et al., 2008). (R)-Goniothalamin caused renal cell death 
primarily by apoptosis, whereas autophagy was involved in (S)-goniothalamin-induced cell 
death (de Fátima et al., 2008). Again, it is important to point out the importance of both, 
biodiversity and organic chemistry to increase and modulate the efficiency of natural 
products to get useful drugs to fight cancer; however, in this particular case, much more 
information is necessary to have a goniothalamin-derivative as a useful drug in cancer 
chemotherapy. Finally, the studies performed until now clearly demonstrate that 
goniothalamin is indeed a lead compound for drug discovery from natural sources. 
Besides the molecules cited here, many other interesting natural products are suitable as 
lead compounds for the design of new drugs (Koehn & Carter, 2005; Gullo et al., 2006; 
Gordaliza, 2007; Lam, 2007; Molinski et al., 2009), such as curcumin, riboflavin, resveratrol, 
and caffeic acid (Aggarwal et al., 2003; Kaminaga et al., 2003; Aggarwal et al., 2004; de Souza 
et al., 2005).  
7. Conclusion 
The potential of nature as a primary source for anticancer drug discovery is astonishing, 
since it offers an unlimited structural diversity of molecular models for bioprospection 
unmatched by any synthetic chemical collection or combinatorial chemistry approach. 
Furthermore, natural products are invaluable as tools for identification of exploitable 
molecular targets and as templates for exploring novel molecular diversity by structural 
modification or by the synthesis of new designed compounds. This not only provides a 
plenty and renewable supply of starting materials for screening, but also contributes to 
improve current libraries with new lead generations. Furthermore, expansions in the fields 
of chemistry and biology have guided new drug discovery strategies to maximize the 
identification of pharmacologically relevant natural product structures. In this context, the 
recent approval of ixabepilone, trabectedin and temsirolimus for cancer treatment (Bailly, 
2009) illustrates the important contribution of natural products, mainly from microbial 
sources, in oncology, even with the increasing use of molecular target-based therapy. 
Therefore, a cooperative interdisciplinary action on modern drug discovery approaches, 
driven by biodiversity, genomic and chemical rationales is emerging with the optimism that 
examining new natural products will continue to turn up useful drugs to treat cancer. In this 
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scenario, Brazilian biodiversity made this country a unique source of leads and structural 
templates from which new therapeutic agents may be developed. Indeed, with so much 
terrestrial and marine diversity awaiting exploration, the Brazilian territory constitutes a 
true treasure for the discovery of new anticancer drugs, providing a further stimulus to the 
preservation of the precious ecosystem where these “golden molecules” can be found. 
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